- Home
- AUDC vs YMAB Comparison
AUDC vs YMAB Comparison
Compare AUDC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- YMAB
- Stock Information
- Founded
- AUDC 1992
- YMAB 2015
- Country
- AUDC Israel
- YMAB United States
- Employees
- AUDC N/A
- YMAB N/A
- Industry
- AUDC Telecommunications Equipment
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- YMAB Health Care
- Exchange
- AUDC Nasdaq
- YMAB Nasdaq
- Market Cap
- AUDC 299.7M
- YMAB 270.5M
- IPO Year
- AUDC 1999
- YMAB 2018
- Fundamental
- Price
- AUDC $8.46
- YMAB $4.48
- Analyst Decision
- AUDC Buy
- YMAB Buy
- Analyst Count
- AUDC 2
- YMAB 11
- Target Price
- AUDC $11.25
- YMAB $18.73
- AVG Volume (30 Days)
- AUDC 76.3K
- YMAB 297.3K
- Earning Date
- AUDC 05-06-2025
- YMAB 03-04-2025
- Dividend Yield
- AUDC 2.00%
- YMAB N/A
- EPS Growth
- AUDC 78.82
- YMAB N/A
- EPS
- AUDC 0.50
- YMAB N/A
- Revenue
- AUDC $242,176,000.00
- YMAB $87,685,000.00
- Revenue This Year
- AUDC $5.11
- YMAB $20.07
- Revenue Next Year
- AUDC $3.81
- YMAB $8.76
- P/E Ratio
- AUDC $19.20
- YMAB N/A
- Revenue Growth
- AUDC N/A
- YMAB 3.38
- 52 Week Low
- AUDC $7.70
- YMAB $4.25
- 52 Week High
- AUDC $12.76
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- AUDC 22.47
- YMAB 39.20
- Support Level
- AUDC $9.24
- YMAB $4.25
- Resistance Level
- AUDC $9.73
- YMAB $4.82
- Average True Range (ATR)
- AUDC 0.27
- YMAB 0.31
- MACD
- AUDC -0.10
- YMAB 0.02
- Stochastic Oscillator
- AUDC 0.00
- YMAB 25.23
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.